Scinai Immunotherapeutics Expands CDMO Platform

Scinai Immunotherapeutics is highlighting the expansion of its Contract Development and Manufacturing Organization (CDMO) platform and its immunology pipeline at BIO-Europe Spring 2026. This strategic development aims to bolster the company's capabilities in biopharmaceutical manufacturing and drug development. By enhancing its CDMO services, Scinai seeks to attract more partnerships and projects, thereby accelerating the progress of its own innovative treatments in inflammation and immunology. The move signifies a commitment to growth and diversification within the competitive biotech landscape.